Pharmaceutical Preformulation and Formulation:  A Practical Guide from Candidate Drug Selection to Commercial Dosage Form Edited by M. Gibson. Interpharm/CRC:  Boca Raton, FL. 2004. 596 + xi pp. $298.95. ISBN.

2005 ◽  
Vol 9 (6) ◽  
pp. 1021-1022 ◽  
2006 ◽  
Vol 34 (1) ◽  
pp. 19-26 ◽  
Author(s):  
Calvert Louden ◽  
David Brott ◽  
Anne Katein ◽  
Thomas Kelly ◽  
Sarah Gould ◽  
...  

In preclinical safety studies, drug-induced vascular injury can negatively impact candidate-drug selection because there are no obvious diagnostic markers for monitoring this pathology preclinically or clinically. Furthermore, our current understanding of the pathogenesis of this lesion is limited. While vasodilatation and increased shear stress appear to play a role, the exact mechanism(s) of injury to the primary target cells, smooth muscle (SMC) and endothelial cell (EC), are unknown. Evaluation of potential novel markers for clinical monitoring with a mechanistic underpinning would add value in risk assessment and risk management. This mini review focuses on the efforts and progress to identify diagnostic markers as well as understanding the mechanism of action in nonrodent drug-induced vascular injury.


2011 ◽  
Vol 43 (3) ◽  
pp. 649-665 ◽  
Author(s):  
S. Qu ◽  
J. C. Gittins

A forwards induction policy is a type of greedy algorithm for Markov decision processes. It is straightforward to implement and is optimal for a large class of models, especially in stochastic resource allocation. In this paper we consider a model for the optimal allocation of resources in pre-clinical pharmaceutical research. We show that although they are not always strictly optimal, forwards induction policies perform well.


2011 ◽  
Vol 43 (03) ◽  
pp. 649-665
Author(s):  
S. Qu ◽  
J. C. Gittins

A forwards induction policy is a type of greedy algorithm for Markov decision processes. It is straightforward to implement and is optimal for a large class of models, especially in stochastic resource allocation. In this paper we consider a model for the optimal allocation of resources in pre-clinical pharmaceutical research. We show that although they are not always strictly optimal, forwards induction policies perform well.


Sign in / Sign up

Export Citation Format

Share Document